The U.S. Food and Drug Administration (FDA) has approved a vagus nerve stimulation (VNS) device for the treatment of rheumatoid arthritis. This marks a significant milestone as it's the first time VNS therapy has received FDA approval for an autoimmune disease. The device, about the size of a pill, works by stimulating the vagus nerve, which can help reduce inflammation associated with rheumatoid arthritis. This approval offers a new treatment option for individuals suffering from this chronic condition and opens the door for potential VNS applications in other autoimmune disorders.